{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:04:53Z","timestamp":1791907493676,"version":"4.3.4"},"reference-count":37,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>The purpose of this prospective, randomized study was to investigate the effectiveness and safety of the ixazomib+cyclophosphamide+dexamethasone (ICd) and ixazomib+dexamethasone (Id) regimens in newly diagnosed multiple myeloma (NDMM) who were elderly and frail and to compare the two regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients were randomly grouped into ICd and Id group. The primary end point was ORR, and patients who received at least two cycles were analyzed. The median follow\u2010up was 13.5\u00a0months. After nine induction cycles, patients were instructed to take single ixazomib for maintenance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall response rate in the ICd and Id groups was 78.9% and 70.6%, respectively, whereas the very good partial remission or better rate was 47.4% and 23.5%, respectively. For the ICd and Id groups, the response rate after 4\u00a0cycles was 76.5% and 57.1%, and the median duration to response was 2 and 4\u00a0months, respectively. Adverse events (AEs) included gastrointestinal intolerance, rash, fatigue, and thrombocytopenia, with severe AEs occurring in 21.1% and 23.5% patients in the ICd and Id groups, respectively, and the AEs were manageable. Both the QLQ\u2010C30 and QLQ\u2010MY20 scales indicated that ICd and Id regimens could help maintain and improve the quality of life(QoL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The ICd and Id regimens might be effective and well\u2010tolerated in elderly and frail patients with NDMM. In addition, a favorable outcome was observed that ICd might tend to cause faster and higher remission than Id regimen without increasing the risk of AEs. The long\u2010term effectiveness and safety of the two regimens need further investigation.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.5422","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T09:58:15Z","timestamp":1668506295000},"page":"6523-6535","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3020-9425","authenticated-orcid":false,"given":"Shutan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hematology, West China Hospital Sichuan University  Chengdu Sichuan Province People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duanzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Dazhou Central Hospital  Dazhou city Sichuan Province People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Dazhou Central Hospital  Dazhou city Sichuan Province People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology Affiliated Hospital of Southwest Medical University  Luzhou Sichuan People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Hematology, West China Hospital Sichuan University  Chengdu Sichuan Province People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2437-9348","authenticated-orcid":false,"given":"Yuping","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Hematology, West China Hospital Sichuan University  Chengdu Sichuan Province People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40320-5_8"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148189"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-626408"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000395"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0002"},{"issue":"5","key":"e_1_2_15_8_1","first-page":"1","article-title":"Longer term follow\u2010up of the randomized phase III trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood","volume":"10","author":"Durie B","year":"2020","journal-title":"Cancer J"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.0044"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv342"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08949.x"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.05.009"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563759"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008787"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-626168"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.185991"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.151.166"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0106-3"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71125-8"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0023"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.2466"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_15_29_1","volume-title":"EORTC QLQ\u2010C30 Scoring Manual","author":"Fayers P","year":"1997"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.2478\/raon-2019-0047"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009584"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.067058"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408922"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0501-4"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.011"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04234-9"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2901-x"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5422","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.5422","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T07:56:09Z","timestamp":1698652569000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.5422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/cam4.5422"],"URL":"https:\/\/doi.org\/10.1002\/cam4.5422","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"assertion":[{"value":"2022-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}